# Minerva Controlled Evidence Intake Authorisation Phase Progress v0.1

## Current Goal

Create deterministic authorisation-gate logic and first-candidate selection metadata for a future no-mutation intake attempt.

## Current Phase

Controlled evidence intake authorisation / first no-mutation candidate selection.

## Current Estimated Progress Before Slice

0% complete.

## Expected Progress After Slice

Approximately 55-65% complete.

## Completed Prior Work

- Governed Evidence Intake Phase Closeout / Intake Runbook v0.1.
- Controlled Evidence Intake Dry-Run / No-Corpus-Mutation v0.1.
- Controlled Evidence Intake Dry-Run Fixture Execution / Review Pack v0.1.
- Controlled Evidence Intake Dry-Run Phase Closeout / No-Mutation Ledger v0.1.

## Work Added By This Slice

- Controlled evidence intake authorisation gate service.
- First no-mutation intake candidate selection service.
- Authorisation gate documentation.
- First candidate documentation.
- Phase progress documentation.
- Focused tests for gate decisions, no-action flags, deterministic candidate ranking, and rejection boundaries.

## Remaining Work

- Create a candidate review pack before any no-mutation intake attempt.
- Define exact candidate fixtures and expected review outputs.
- Keep ingestion, corpus mutation, Code Evidence ingestion, DB access, live retrieval, live LLM use, final answer generation, chat exposure, endpoint exposure, runtime integration, deployment, and production deferred.

## Quality Guardrails

This phase remains local, deterministic, service/docs/tests only. It has no API route, UI, DB connection, migration, corpus write, evidence store write, retrieval backend change, LLM call, final answer generation, workforce-platform change, or analytics runtime integration.

## Recommended Next Slice

Controlled Evidence Intake Candidate Review Pack / No-Mutation Intake Attempt Readiness v0.1.

## Developer Handoff

Continue from approximately 55-65% complete. Use the new authorisation gate and first candidate selector as review metadata only, and do not treat future no-mutation candidate eligibility as current intake authorisation.
